PL3247805T3 - Sposób oceny odpowiedzi pacjentów z ataksją-teleangiektazją na leczenie glukokortykoidami - Google Patents

Sposób oceny odpowiedzi pacjentów z ataksją-teleangiektazją na leczenie glukokortykoidami

Info

Publication number
PL3247805T3
PL3247805T3 PL16709121T PL16709121T PL3247805T3 PL 3247805 T3 PL3247805 T3 PL 3247805T3 PL 16709121 T PL16709121 T PL 16709121T PL 16709121 T PL16709121 T PL 16709121T PL 3247805 T3 PL3247805 T3 PL 3247805T3
Authority
PL
Poland
Prior art keywords
evaluating
response
ataxia telangiectasia
glucocorticoids treatment
patients
Prior art date
Application number
PL16709121T
Other languages
English (en)
Inventor
Mauro Magnani
Sara Biagiotti
Michele MENOTTA
Original Assignee
Erydel S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erydel S.P.A. filed Critical Erydel S.P.A.
Publication of PL3247805T3 publication Critical patent/PL3247805T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/142Toxicological screening, e.g. expression profiles which identify toxicity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL16709121T 2015-01-19 2016-01-19 Sposób oceny odpowiedzi pacjentów z ataksją-teleangiektazją na leczenie glukokortykoidami PL3247805T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM20150022 2015-01-19
PCT/IB2016/050238 WO2016116850A1 (en) 2015-01-19 2016-01-19 Method of evaluating the response of ataxia telangiectasia patients to glucocorticoids treatment
EP16709121.4A EP3247805B1 (en) 2015-01-19 2016-01-19 Method of evaluating the response of ataxia telangiectasia patients to glucocorticoids treatment

Publications (1)

Publication Number Publication Date
PL3247805T3 true PL3247805T3 (pl) 2019-12-31

Family

ID=52574385

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16709121T PL3247805T3 (pl) 2015-01-19 2016-01-19 Sposób oceny odpowiedzi pacjentów z ataksją-teleangiektazją na leczenie glukokortykoidami

Country Status (9)

Country Link
US (1) US10619208B2 (pl)
EP (1) EP3247805B1 (pl)
JP (1) JP6359196B2 (pl)
CN (1) CN107532201B (pl)
AU (1) AU2016209976B2 (pl)
CA (1) CA2974181C (pl)
ES (1) ES2732739T3 (pl)
PL (1) PL3247805T3 (pl)
WO (1) WO2016116850A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018112409A1 (en) * 2016-12-15 2018-06-21 Recursion Pharmaceuticals, Inc. Methods of treating ataxia-telangiectasia
US12152274B2 (en) 2017-09-29 2024-11-26 Pharmabio Corporation Quality management method for regeneration medical product or the like by using standardized expression amount

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858661A (en) * 1995-05-16 1999-01-12 Ramot-University Authority For Applied Research And Industrial Development Ataxia-telangiectasia gene and its genomic organization
CN101888776B (zh) * 2007-09-20 2015-03-11 罗切斯特大学 治疗或预防炎性病症的方法和组合物
JP2012171895A (ja) * 2011-02-18 2012-09-10 Nagoya City Univ 毛細血管拡張性失調症治療薬及びその用途
CN103031365B (zh) * 2011-09-30 2014-11-26 益善生物技术股份有限公司 一种atm基因突变检测特异性引物和液相芯片
CN106701709B (zh) * 2013-05-20 2020-02-07 中南大学湘雅医院 Atm基因突变体及其应用

Also Published As

Publication number Publication date
CA2974181C (en) 2022-06-21
WO2016116850A1 (en) 2016-07-28
EP3247805B1 (en) 2019-03-27
BR112017015527A2 (pt) 2018-04-10
CN107532201A (zh) 2018-01-02
ES2732739T3 (es) 2019-11-25
EP3247805A1 (en) 2017-11-29
AU2016209976A1 (en) 2017-08-10
US20180016637A1 (en) 2018-01-18
CN107532201B (zh) 2021-05-11
AU2016209976B2 (en) 2021-11-11
CA2974181A1 (en) 2016-07-28
JP2018503381A (ja) 2018-02-08
JP6359196B2 (ja) 2018-07-18
US10619208B2 (en) 2020-04-14

Similar Documents

Publication Publication Date Title
ZA202006746B (en) Methods of treatment
ZA201705673B (en) Methods for treating skin
IL257561A (en) Methods for treating inflammatory diseases
IL253118A0 (en) Methods for treating inflammatory diseases
ZA201706059B (en) Method of treatment with tradipitant
GB201514760D0 (en) Compounds and method of use
GB201410116D0 (en) Method of treatment
ZA201705877B (en) Method of treating diseases
IL257764B (en) Methods for treatment of diseases
GB201706406D0 (en) Method of treatment
EP3684342C0 (en) TREATMENT PROCEDURES
GB201815588D0 (en) Method of treatment
IL253847A0 (en) Methods of treating diseases
ZA201705847B (en) Treatment of pain
IL253028B (en) treatment method
GB201511799D0 (en) Composition and methods of treatment
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
GB201602802D0 (en) Method of treatment
GB201515244D0 (en) Treatment of inflammatory disease or condition
PL3247805T3 (pl) Sposób oceny odpowiedzi pacjentów z ataksją-teleangiektazją na leczenie glukokortykoidami
IL255012A0 (en) Preparations and methods for treating skin conditions
GB201512139D0 (en) Methods of treatment
GB201500555D0 (en) Method and device for the treatment of diseases
GB201720439D0 (en) Method of treatment
GB201718589D0 (en) Method of treatment